Tandem Diabetes (TNDM) Misses Q3 EPS by 28c, Revenues Beat; Offers FY18 Revenue Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Tandem Diabetes Care Reports Third Quarter 2018 Financial Results
November 1, 2018 4:05 PM EDTSAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2018.
Third Quarter 2018 Results
In comparing the third quarter of 2018 to the same period of 2017:
Pump shipments increased 118 percent to 8,434 pumps from 3,868 pumps Sales increased 71 percent to $46.3 million from $27.0 million Operating margin improved to negative 34 percent from negative 49 percentWe delivered a record-setting quarter in terms of robust... More
